In spite of the importance of effective antimicrobials to modern medicine and growing recognition of the health and economic threat posed by antimicrobial resistance (AMR), market challenges have impeded sustainable investment in the development of new products to prevent and treat bacterial infections.
There are ongoing conversations on incentives to stimulate AMR-relevant research and development. New value frameworks that capture the full benefit of these products are fundamental to enable successful implementation of these incentives. These frameworks can be used to ensure the incentives for development are commensurate with the benefits that novel antibiotics and vaccines bring patients, health care systems, and society.
This session will examine how we can better assess the value of new antimicrobials to individuals, health care systems, and society; how the unique attributes of novel antibiotics can be considered in reimbursement decision-making.
Ability Level: All
Session ID: 19782